Marinus Pharmaceuticals Inc (FRA:61Y)
€ 0.302 0.002 (0.67%) Market Cap: 17.09 Mil Enterprise Value: 30.25 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Q2 2021 Marinus Pharmaceuticals Inc Earnings Call Transcript

Aug 10, 2021 / 12:30PM GMT
Release Date Price: €10.8 (-0.92%)
Operator

Greetings, and welcome to the Marinus Pharmaceuticals Second Quarter 2021 Business Update call. (Operator Instructions)

And now it is my pleasure to introduce your host, Sasha Damouni Ellis, Vice President of Corporate Affairs and Investor Relations. You may begin, Ms. Damouni Ellis.

Sasha Damouni Ellis
Marinus Pharmaceuticals, Inc. - VP of Corporate Affairs & IR

Thank you. With me from Marinus are Dr. Scott Braunstein, Chief Executive Officer; Dr. Joe Hulihan, Chief Medical Officer; Steve Pfanstiel, Chief Financial Officer; and Kimberly McCormick, Senior Vice President of Regulatory affairs. Also on the call is Christy Shafer, Chief Commercial Officer, who will be available during Q&A. Before we begin, I would like to remind everyone that some of the statements made today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot